Interstitial pneumonitis associated with trastuzumab emtansine
- 14 November 2018
- journal article
- research article
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 25 (7), 1798-1800
- https://doi.org/10.1177/1078155218813716
Abstract
Subscription and open access journals from SAGE Publishing, the world's leading independent academic publisher.Keywords
This publication has 14 references indexed in Scilit:
- Interstitial Pneumonitis Secondary to Trastuzumab: A Case Report and Literature ReviewCase Reports in Oncology, 2017
- Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trialThe Lancet Oncology, 2017
- Interstitial lung diseaseEuropean Respiratory Review, 2014
- Trastuzumab Emtansine for HER2-Positive Advanced Breast CancerThe New England Journal of Medicine, 2012
- Delayed Paclitaxel-Trastuzumab-Induced Interstitial Pneumonitis in Breast CancerCase Reports in Oncology, 2011
- Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based ReviewJournal of Clinical Oncology, 2010
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug ConjugateCancer Research, 2008
- Trastuzumab (Herceptin)‐associated lung injuryRespirology, 2006
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerThe New England Journal of Medicine, 2005
- A method for estimating the probability of adverse drug reactionsClinical Pharmacology & Therapeutics, 1981